Skip to content

More evidence that antiretrovirals reduce the risk of non-HIV illnesses at lower CD4 cell counts

Patients staying on first-line HIV treatment combinations for longer

Study shows patients in their 30s at time of HIV infection have best response to HIV therapy

Poor results using non-medical HIV counsellors to screen for treatment eligibility in Malawi

How does abacavir/3TC compare to tenofovir/FTC? ACTG5202 and GSK studies disagree

Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks

Efavirenz superior to lopinavir/ritonavir in very advanced HIV, Mexican trial shows

Swiss statement that ‘undetectable equals uninfectious’ creates more controversy in Mexico City

Age may predict response to HIV treatment